^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    ELTD1 (Adhesion G Protein-Coupled Receptor L4)

    i
    Other names: ELTD1, Adhesion G Protein-Coupled Receptor L4, EGF, Latrophilin And Seven Transmembrane Domain-Containing Protein 1, EGF, Latrophilin And Seven Transmembrane Domain Containing 1, EGF-TM7-Latrophilin-Related Protein, Lnc-ADGRL4-2, ETL Protein, KPG_003
    1year
    Comprehensive analysis of bulk, single-cell RNA sequencing, and spatial transcriptomics revealed IER3 for predicting malignant progression and immunotherapy efficacy in glioma. (PubMed, Cancer Cell Int)
    In this study, we identified IER3 upregulation as an essential biomarker that could assist in adjuvant therapy and prognosis prediction for gliomas.
    Journal • IO biomarker
    |
    CCL2 (Chemokine (C-C motif) ligand 2) • PDGFA (Platelet Derived Growth Factor Subunit A) • ELTD1 (Adhesion G Protein-Coupled Receptor L4) • TGFBI (Transforming Growth Factor Beta Induced)
    |
    BRAF mutation
    |
    Tafinlar (dabrafenib)
    over1year
    Elucidating the role of tumor-associated ALOX5+ mast cells with transformative function in cervical cancer progression via single-cell RNA sequencing. (PubMed, Front Immunol)
    The prognostic model constructed based on the C2 ALOX5+MCs subset demonstrated excellent predictive value. These findings offer a fresh perspective for clinical decision-making in CC.
    Journal
    |
    CALR (Calreticulin) • IL32 (Interleukin 32) • ELTD1 (Adhesion G Protein-Coupled Receptor L4) • TNFRSF12A (TNF Receptor Superfamily Member 12A)
    over1year
    Apoptotic effect of melatonin on ER-positive breast cancer cell lines: ADGRL4 gene expression and promoter methylation. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)
    We found that melatonin has anti-cancer effects on BC cells. In addition, ADGRL4 expression can potentially be used as a prognostic biomarker in BC.
    Preclinical • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • ELTD1 (Adhesion G Protein-Coupled Receptor L4)
    over1year
    Histopathological growth pattern and vessel co-option in intrahepatic cholangiocarcinoma. (PubMed, Med Mol Morphol)
    iCCA (sub)types and HGPs were closely related to vessel co-option and immune-related factors (lymphatic vessels, lymphocytes, and neutrophils). In conclusion, HGPs and vascular mechanisms characterize iCCA (sub)types and vessel co-option linked to the immune microenvironment.
    Journal
    |
    ELTD1 (Adhesion G Protein-Coupled Receptor L4)
    over1year
    ELTD1 Review: New Regulator of Angiogenesis in Glioma. (PubMed, Curr Health Sci J)
    This review aimed to translate these insights into effective clinical treatments. However, several gaps remain in our knowledge regarding ELTD1 ligands and their potential involvement in other physiological or pathological processes that future research can address to elucidate the role of ELTD1 in cancer, through angiogenesis and other intracellular pathways.
    Review • Journal
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit) • ELTD1 (Adhesion G Protein-Coupled Receptor L4)
    |
    ELTD1 expression
    almost2years
    Broad next generation integrated sequencing of myelofibrosis identifies disease-specific and age-related genomic alterations. (PubMed, Clin Cancer Res)
    Our results illustrate that evolution of MF from ET/PV/PrePMF likely advances with age, accumulation of mutations, and activation of proliferative pathways. The genes and pathways identified by integrated genomics approach provide insight into disease transformation and progression, and potential targets for therapeutic intervention.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • ABL1 (ABL proto-oncogene 1) • NRAS (Neuroblastoma RAS viral oncogene homolog) • BCR (BCR Activator Of RhoGEF And GTPase) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NF1 (Neurofibromin 1) • JAK2 (Janus kinase 2) • ASXL1 (ASXL Transcriptional Regulator 1) • SRSF2 (Serine and arginine rich splicing factor 2) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • CALR (Calreticulin) • ELTD1 (Adhesion G Protein-Coupled Receptor L4) • DNASE1L3 (Deoxyribonuclease 1 Like 3)
    |
    KRAS mutation • NRAS mutation • NF1 mutation • RAS mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation
    almost2years
    Single-cell analysis reveals ADGRL4+ renal tubule cells as a highly aggressive cell type in clear cell renal cell carcinoma. (PubMed, Sci Rep)
    ETS1 and ELK3 -dominant GRNs were remarkably activated in ADGRL4+ renal tubule cells, functionally, knockdown of ELK3 in A498 significantly disturbedaffected the cell migration and invasion. ADGRL4+ renal tubule cells, which were highly metastatic and invasive, might be an essential cell subcluster for ccRCC, and ADGRL4 could be used a novel therapeutic target.
    Journal
    |
    ETS1 (ETS Proto-Oncogene 1) • ELTD1 (Adhesion G Protein-Coupled Receptor L4) • PTHLH (Parathyroid Hormone Like Hormone) • BEX2 (Brain Expressed X-Linked 2) • KLRB1 (Killer Cell Lectin Like Receptor B1) • NNMT (Nicotinamide N-Methyltransferase)
    almost2years
    ADGRL4 Promotes Cell Growth, Aggressiveness, EMT, and Angiogenesis in Neuroblastoma via Activation of ERK/STAT3 Pathway. (PubMed, Curr Mol Med)
    To conclude, the downregulation of ADGRL4 may inhibit cell growth, aggressiveness, EMT, and angiogenesis in NB by inactivating the ERK/STAT3 signaling pathway.
    Journal
    |
    ELTD1 (Adhesion G Protein-Coupled Receptor L4)
    2years
    Tanshinone IIA normalized hepatocellular carcinoma vessels and enhanced PD-1 inhibitor efficacy by inhibiting ELTD1. (PubMed, Phytomedicine)
    This study reveals a new mechanism between TSA and ELTD1 for vascular normalization, suggesting that therapeutic or pharmacological intervention with ELTD1 may enhance the efficacy of PD-1 inhibitors in HCC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    JAK2 (Janus kinase 2) • JAK1 (Janus Kinase 1) • ELTD1 (Adhesion G Protein-Coupled Receptor L4) • TJP1 (Tight Junction Protein 1) • CLDN5 (Claudin 5)
    |
    ELTD1 expression
    4years
    A tale of two multi-focal therapies for glioblastoma: An antibody targeting ELTD1 and nitrone-based OKN-007. (PubMed, J Cell Mol Med)
    In this study, we sought to compare anti-ELTD1 and OKN-007 therapies, as single agents and combined, against bevacizumab, a commonly used therapeutic agent against GBM, in a human G55 xenograft mouse model. Anti-ELTD1 treatment was shown to be as effective as OKN therapy. Both OKN and anti-ELTD1 therapies show promise as potential single-agent multi-focal therapies for GBM patients.
    Journal
    |
    NOTCH1 (Notch 1) • KDR (Kinase insert domain receptor) • ELTD1 (Adhesion G Protein-Coupled Receptor L4)
    |
    Avastin (bevacizumab) • disufenton sodium (OKN-007)
    4years
    ELTD1 as a multi-focal target for malignant gliomas: preclinical studies. (PubMed, Neurooncol Adv)
    Lastly, anti-ELTD1 treatments successfully increased apoptotic activity within the tumor region. Our data suggest that anti-ELTD1 therapies would be effective against malignant gliomas by having a multi-focal effect and targeting all four aspects of tumorigenesis.
    Preclinical • Journal
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • CD44 (CD44 Molecule) • CASP3 (Caspase 3) • EGF (Epidermal growth factor) • ELTD1 (Adhesion G Protein-Coupled Receptor L4)